Curaleaf Holdings (CURLF) Accumulated Expenses (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Accumulated Expenses of $110.5 million for Q4 2025, up 8.13% year-on-year from $102.2 million in Q4 2024, and up 8.13% on a QoQ basis from $102.2 million in Q4 2024.
Curaleaf Holdings (CURLF) Accumulated Expenses (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Accumulated Expenses for 7 consecutive years, with $110.5 million the latest figure, recorded in Q4 2025.
- Quarterly Accumulated Expenses rose 8.13% year-over-year to $110.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $110.5 million (up 8.13% YoY) and the FY2025 annual result came in at $110.5 million, up 8.13% from the prior year.
- Accumulated Expenses improved to $110.5 million in Q4 2025 per CURLF's latest filing, from $102.2 million in the prior quarter.
- Over the last five years, Accumulated Expenses for CURLF reached as high as $95.8 billion in Q1 2022 and fell as low as $54.4 million in Q1 2021.
- A 5-year average of $6.5 billion and a median of $101.3 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 176163.61% — and 2023, when it decreased 1.94%.
- Year by year, Accumulated Expenses stood at $87.0 million in 2021, then increased by 18.79% to $103.3 million in 2022, then decreased by 1.94% to $101.3 million in 2023, then advanced by 0.87% to $102.2 million in 2024, then climbed by 8.13% to $110.5 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $110.5 million, $102.2 million, and $115.6 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110.49 Mn |
| Dec 31, 2024 | 102.19 Mn |
| Sep 30, 2024 | 115.61 Mn |
| Jun 30, 2024 | 107.74 Mn |
| Dec 31, 2023 | 101.31 Mn |
| Sep 30, 2023 | 100.97 Mn |
| Jun 30, 2023 | 105.46 Mn |
| Dec 31, 2022 | 103.31 Mn |
| Sep 30, 2022 | 95.34 Mn |
| Jun 30, 2022 | 89.46 Mn |
| Mar 31, 2022 | 95.83 Bn |
| Dec 31, 2021 | 86.97 Mn |
| Sep 30, 2021 | 80.65 Mn |
| Jun 30, 2021 | 59.67 Mn |
| Mar 31, 2021 | 54.37 Mn |
| Dec 31, 2020 | 57.48 Mn |
| Sep 30, 2020 | 44.81 Mn |
| Dec 31, 2019 | 18.02 Mn |